Banks like Mizuho, Deutsche Bank, and Goldman Sachs maintained or raised ratings for Harmony Biosciences, citing benefits from tariffs and onshoring trends for AI stocks.
3 reports, 2 independent
Updated Tue 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Banks like Mizuho, Deutsche Bank, and Goldman Sachs maintained or raised ratings for Harmony Biosciences, citing benefits from tariffs and onshoring trends for AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Banks predict rate hikes due to inflation fueled by Trump's tariffs.1 source
Major banks maintained or raised ratings for Harmony Biosciences, linking the action to AI stock benefits from tariffs.1 source
Keep exploring
The entities involved
-
Goldman Sachs
American investment bank
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Deutsche Bank
German global banking and financial services company
-
Mizuho Securities
Japanese investment banking company
- Financial firms, including Mizuho and HDFC, provided forecasts on the rupee's stability and depreciation against the greenback.
- Geode Capital Management, Mizuho Securities, and Manufacturers Life Insurance Company increased their holdings and raised their target price/rating on MBX Biosciences stock.
Related events
Coverage
Newest first; wire copies grouped- aol.com
- Insider MonkeyHarmony Biosciences Advances Pipeline While Navigating Analyst Caution Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ senti
- Unknown outlet